Pour découvrir comment collaborer plus efficacement avec le Centre des cancers du poumon, l’équipe dirigée par Alfredo Addeo MD vous invite jeudi 10 novembre à une journée d’immersion auprès des différents spécialistes #CancerDuPoumon #cancer #poumon hug.ch/evenement/jour…

1/ Prof. Manuela Eicher, Dr. Alfredo Addeo MD and Dr. Corbiere Tourane from the Patient Lab open our first international #PPI workshop. What are you looking forward to the most? Follow #labpat and Klara Soukup, André Lopes, Emma Kinloch and Suis(s)ePatiente 🟣 Christine Bienvenu for live updates

2/ Prof. Manuela Eicher, Dr. Alfredo Addeo MD et Dr. Corbiere Tourane du Laboratoire des Patients ouvrent le 1er Workshop international de #IPP ! Qu'attendez-vous le plus ? Suivez #labpat et Klara Soukup, André Lopes, Emma Kinloch et Suis(s)ePatiente 🟣 Christine Bienvenu pour des mises à jour en direct

For MET-deregulated aNSCLC 🫁 several targeted therapies (mainly for METex14 mut) have been developed. MET ampl is a common resist. mec. in oncogene driven NSCLC🧬.We have tried to update most recent data authors.elsevier.com/sd/article/S15…. Thanks to all authors Lizza Hendriks Martin Reck

🔥Out now! “Rationalizing rules for #immunotherapy combination trials: About time for #precision immunotherapy” with Vivek Subbiah, MD OncoAlert Mayo Clinic Hematology-Oncology Fellowship MD Anderson Cancer Center
➡️ Patient Selection will be 🗝️ for future of # IO, we propose a 🎯 driven approach
➡️ 📝learned from IDOs!

Enjoyed working on this review on #KRAS with dynamic collaborators and investigators Drs. Kaushal Parikh Alfredo Addeo MD Aakash Desai, MD, MPH Vivek Subbiah, MD Alex Friedlaender #LCSM

jhoonline.biomedcentral.com/articles/10.11…

Sai-Hong Ignatius Ou Oliver Gautschi Post-marketing authorization under U.S. FDA accelerated approval required to conduct a trial of sotorasib 960 mg vs 240 mg. The trial has completed patients accrual. Waiting for results.
accessdata.fda.gov/drugsatfda_doc…

Great overview of immunotherapy in the perioperative setting for NSCLC by Dr. Joshua Reuss at #DCLung22 . New options based on IMpower 010, PEARLS, NADIM, CheckMate 816 with atezolizumab approved as adjuvant and nivolumab approved as neoadjuvant. Impressive outcomes!

An interesting update on a selection of LBAs from the Presidential Symposia at #ESMO22 with experts, Alfredo Addeo MD & Ray Manneh Kopp giving their perspectives on a selection of late-breaking abstracts
#NSCLC#CRC#oncology
Go to the full video here ow.ly/82e850Ljogv
#MedEd

Very proud of my first Neuro oncology Fellow Dr Barbara Muoio from Ticino, congratulations on your great presentation on the predictive value of methyloma in GBM at the Swiss Italian neuro oncology meeting 2022 Ente Ospedaliero Cantonale HUG Université de Genève

We need to work together to advocate for more #lungcancer research funding.

More reseach = more life.

As the leading cause of cancer death, lung cancer should not be the least funded. Thanks Dr Christine Lovly for your message

#MoreResearchMoreLife #LCAM #StrongerTogether

Honored to chair this great session on Allogenic genetically engineered cells alongside David Quach #ENA2022 EORTC AACR NCI joint meeting today in Barcelona.HUG Université de Genève Fondation ISREC

Check out this update from#ESMO22 on a selection of LBA'S from the Presidential Symposia at ESMO 2022.
Expert perspectives on key data&new abstarcts with Alfredo Addeo MD &@raymanneh in #NSCLC#CRC#ProstateCancer #RCC
Go to the full video here ow.ly/Hol250LkhFR
#oncology #MedEd

Alfredo Addeo MD Indeed. Fantastic academic collaboration. 22 centres from 9 countries! It was an amazing experience. Many thanks to all involved!

Drinks drinks drinks mare….. see u very soon

Jarushka Naidoo JTO & JTO CRR Another thought provoking result for me from this study was the really good outcome for patients with compound common+uncommon mutations, looks much better than the common EGFR with PFS of 30 m and DOR of 46 m

Aakash Desai, MD, MPH BMC Kaushal Parikh Giuseppe Banna Stephen V Liu, MD Alex Friedlaender Vivek Subbiah, MD Alfredo Addeo MD OncoAlert David Gandara H. Jack West, MD Ben Solomon Sanjay Popat Luis E Raez KRASKickers Charu Aggarwal, MD, MPH Balazs Halmos Christine Lovly These figures, my friend!

UNICORN: An international real-world study of #osimertinib for uncommon #EGFR mutations as a first line setting further clarifies the drug's impact in patients with uncommon EGFR mutations. bit.ly/3StwroQ #LCSM Jair Bar Martin Reck Hochmair Maximilian Sandip Patel MD Shiruyeh Schokrpur, MD, PhD

Very happy to see this out. Huge congratulations to all the people who worked to get the data